{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:06:25Z","timestamp":1790996785560,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jtos.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T12:51:48Z","timestamp":1565268708000},"page":"828-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study"],"prefix":"10.1016","volume":"17","author":[{"given":"Ellen","family":"Shorter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Harthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Hartwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Migneco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Morettin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Huecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Than","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mae O.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2019.08.005_bib1","series-title":"Care of the patient with conjunctivitis","author":"Optometric Clinical Pratice Guideline","year":"2002"},{"key":"10.1016\/j.jtos.2019.08.005_bib2","series-title":"Conjunctivitis - limited revision","author":"Preferred Pratice Pattern Guidelines","year":"2018"},{"key":"10.1016\/j.jtos.2019.08.005_bib3","article-title":"A guide to understanding adenovirus, the disease it causes and the best ways to treat these conditions","author":"Abelson","year":"2010","journal-title":"Rev Ophthalmol"},{"key":"10.1016\/j.jtos.2019.08.005_bib4","article-title":"What's the buzz about betadine?","author":"Shovlin","year":"2011","journal-title":"Rev Optom"},{"issue":"5","key":"10.1016\/j.jtos.2019.08.005_bib5","first-page":"323","article-title":"[Personal experience with the use of Betadine gtt. in the treatment of epidemic viral keratoconjunctivitis]","volume":"50","author":"Pernicky","year":"1994","journal-title":"Cesk Oftalmol"},{"issue":"3","key":"10.1016\/j.jtos.2019.08.005_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-2008-1046272","article-title":"[Epidemic keratoconjunctivitis: treatment results during an epidemic]","volume":"197","author":"Hutter","year":"1990","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.jtos.2019.08.005_bib7","series-title":"How to manage adenoviral conjunctivitis","author":"Than","year":"2014"},{"key":"10.1016\/j.jtos.2019.08.005_bib8","series-title":"Alcon new drug application for betadine","author":"Chambers","year":"2002"},{"issue":"Suppl 1","key":"10.1016\/j.jtos.2019.08.005_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000057733","article-title":"Ocular applications of povidone-iodine","volume":"204","author":"Isenberg","year":"2002","journal-title":"Dermatology"},{"issue":"12","key":"10.1016\/j.jtos.2019.08.005_bib10","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0161-6420(91)32052-9","article-title":"Prophylaxis of endophthalmitis with topical povidone-iodine","volume":"98","author":"Speaker","year":"1991","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"10.1016\/j.jtos.2019.08.005_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000057738","article-title":"Antimicrobial effectiveness of povidone-iodine and consequences for new application areas","volume":"204","author":"Reimer","year":"2002","journal-title":"Dermatology"},{"issue":"8","key":"10.1016\/j.jtos.2019.08.005_bib12","first-page":"968","article-title":"The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis","volume":"66","author":"Yazar","year":"2016","journal-title":"J Pak Med Assoc"},{"issue":"1","key":"10.1016\/j.jtos.2019.08.005_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/15569527.2014.888077","article-title":"Povidone iodine in the treatment of adenoviral conjunctivitis in infants","volume":"34","author":"Ozen Tunay","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"10.1016\/j.jtos.2019.08.005_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jop.2011.0082","article-title":"Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: a pilot study","volume":"28","author":"Trinavarat","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jtos.2019.08.005_bib15","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1111\/aos.13416","article-title":"Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study","volume":"95","author":"Kovalyuk","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2019.08.005_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2018.05.012","article-title":"Randomized, controlled, phase 2 trial of povidone-iodine\/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis","volume":"194","author":"Pepose","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2019.08.005_bib17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3109\/02713683.2014.964419","article-title":"Dexamethasone\/povidone eye drops versus artificial tears for treatment of presumed viral conjunctivitis: a randomized clinical trial","volume":"40","author":"Pinto","year":"2015","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.jtos.2019.08.005_bib18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12325-009-0062-1","article-title":"A combination povidone-iodine 0.4%\/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis","volume":"26","author":"Pelletier","year":"2009","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jtos.2019.08.005_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00006324-199303000-00011","article-title":"CCLRU standards for success of daily and extended wear contact lenses","volume":"70","author":"Terry","year":"1993","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jtos.2019.08.005_bib20","author":"QuickVue Adenoviral Conjunctivitis Test"},{"key":"10.1016\/j.jtos.2019.08.005_bib21","article-title":"Dilute povidone-iodine prophylaxis maintains safety while improving patient comfort after intravitreal injections","author":"Peden","year":"2018","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.jtos.2019.08.005_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/15569527.2017.1291665","article-title":"Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections","volume":"36","author":"Saedon","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"issue":"7","key":"10.1016\/j.jtos.2019.08.005_bib23","first-page":"732","article-title":"Effect of povidone iodine 5% on the cornea","volume":"94","author":"Ridder","year":"2017","journal-title":"Vis Subjective Comf"},{"issue":"1","key":"10.1016\/j.jtos.2019.08.005_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1444-0938.1999.tb06778.x","article-title":"The characteristics of corneal staining in successful daily and extended disposable contact lens wearers","volume":"82","author":"Jalbert","year":"1999","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.jtos.2019.08.005_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2018.08.056","article-title":"Randomized, controlled, phase 2 trial of povidone-iodine\/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis","volume":"197","author":"Cinal","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.08.005_bib26","series-title":"Determinants of outcomes of adenoviral keratoconjunctivitis.","first-page":"1344","article-title":"Ophthalmology","volume":"125","author":"Lee","year":"2018"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012419301429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012419301429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:35:58Z","timestamp":1761539758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012419301429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1542012419301429"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2019.08.005","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}